Sergio Szyldergemajn

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau et al. · The Lancet Oncology · 2020 · 130 citations

Medicine, Oncology, Radiation Oncology +11

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

María Elena Elez, Josep Tabernero, David Geary et al. · Clinical Cancer Research · 2014 · 89 citations

Pharmacy, Oncology, Pharmacology +16

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

María‐Victoria Mateos, María Teresa Cibeira, Paul G. Richardson et al. · Clinical Cancer Research · 2010 · 74 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma

V. Ribrag, Dolores Caballero, Christophe Fermé et al. · Haematologica · 2012 · 60 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Christophe Le Tourneau, Yungan Tao, Carlos Gomez‐Roca et al. · Clinical Cancer Research · 2020 · 31 citations · Full text

Medicine, Oncology, Pharmacology +15